Absorption, excretion, distribution, and metabolism of 2-(5H-[1] benzopyrano [2, 3-b] pyridin-7-yl) propionic acid (Y-8004), a new anti-inflammatory agent, were investigated in rats and mice by the use of
14C-labeled compound (
14C-Y-8004). When the radioactive compound was given to rats orally or intraperitoneally, about 50% of the given radio-activity (
14C) was excreted in urine and 40% in feces during 72 hr, while about 80% in urine and 20% in feces after oral administration to mice. Approximately 55-60% was recovered in rat bile during 24 hr after oral administration. The highest blood level of
14C was obtained at 0.5-1 hr after oral administration to rats and mice. A good correlation was observed between blood level and dose level. However, apparent species difference in the blood
14C concentration and its disappearance rate were observed between rats and mice. When
14C-Y-8004 was orally administered to bileduct-cannulated rat, the blood
14C concentration and its disappearance rate came close to those of normal mice. The highest concentration of
14C was observed in the serum and relatively high levels in the liver and kidney of rats and mice after oral administration of
14C-Y-8004. In both animals, most of
14C in the serum existed as unchanged material bound to serum protein. Thin-layer chromatography after enzymic, acid, and alkaline hydrolysis experiments showed that the major metabolite in urine and bile of rats was Y-8004 acylglucuronide and in urine of mice Y-8004 acylglucoside. The present investigation provides the first evidence for the formation of an acylglucoside of a drug in mammals.
抄録全体を表示